330 related articles for article (PubMed ID: 31820339)
1. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
Kim WS; Buske C; Ogura M; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Osmanov D; Kwak LW; Lee SJ; Lee SY; Bae YJ; Coiffier B
Lancet Haematol; 2017 Aug; 4(8):e362-e373. PubMed ID: 28712940
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
6. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Jurczak W; Moreira I; Kanakasetty GB; Munhoz E; Echeveste MA; Giri P; Castro N; Pereira J; Akria L; Alexeev S; Osmanov E; Zhu P; Alexandrova S; Zubel A; Harlin O; Amersdorffer J
Lancet Haematol; 2017 Aug; 4(8):e350-e361. PubMed ID: 28712941
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
9. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
[TBL] [Abstract][Full Text] [Related]
10. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
11. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.
Niederwieser D; Hamm C; Cobb P; Mo M; Forsyth C; Tucci A; Hanes V; Delwail V; Hajek R; Chien D
Target Oncol; 2020 Oct; 15(5):599-611. PubMed ID: 33044684
[TBL] [Abstract][Full Text] [Related]
13. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
Viswabandya A; Shah S; Mukhopadhyay A; Nagarkar RV; Batra SS; Lopez-Lazaro L; Kankanwadi S; Srivastava A
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31809224
[TBL] [Abstract][Full Text] [Related]
15. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Burmester G; Drescher E; Hrycaj P; Chien D; Pan Z; Cohen S
Clin Rheumatol; 2020 Nov; 39(11):3341-3352. PubMed ID: 32876780
[TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
